Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.75 |
| ▸ | HTT | P42858 | 2/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.75 |
| ▸ | BRAF | P15056 | 1/20 | 0.75 |
| ▸ | THRB | P10828 | 1/20 | 0.75 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15783186 | 0.90 | KDR (0.81) | KDRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL14235459 | 0.88 | KDR (0.78) | KDRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL31060934 | 0.87 | KDR (1.00) | KDRMEN1KMT2AALDH1A1HTT | |
| SCHEMBL3021915 | 0.87 | KDR (1.00) | KDRMEN1KMT2AALDH1A1HTT | |
| SCHEMBL3018051 | 0.86 | HTT (1.00) | KDRMEN1KMT2AALDH1A1HTT | |
| SCHEMBL3027890 | 0.86 | MAPT (1.00) | KDRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL15783189 | 0.86 | KDR (0.75) | KDRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL7912018 | 0.85 | KDR (0.74) | KDRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL3024303 | 0.84 | MAPT (1.00) | KDRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL2211831 | 0.84 | MAPT (1.00) | KDRMEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9316633-B2 | Methods for identifying inhibitors of solute transporters | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-04-19 | — | — | US | disclosed |
| US-20100190796-A1 | METHODS FOR IDENTIFYING INHIBITORS OF SOLUTE TRANSPORTERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190796-A1 | METHODS FOR IDENTIFYING INHIBITORS OF SOLUTE TRANSPORTERS | SLC2A1, SLC2A3, SLC2A8 | KDR 2707/4885MEN1 1626/4885KMT2A 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.